[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359-386.
[2] Liu J, Tsai H, Hsu S, et al. Clear cell and non-clear cell hepatocellular carcinoma: a case report and literature review. Kaohsiung J Med Sci. 2004; 20:78–81.
[3] Ji S, Li Q, Dong H. Therapy and prognostic features of primary clear cell carcinoma of the liver. World J Gastroenterol. 2010; 16:764.
[4] Emile JF, Lemoine A, Azoulay D, et al. Histological, genomic and clinical heterogeneity of clear cell hepatocellular carcinoma. Histopathology. 2001; 38: 225–231.
[5] Adamek HE, Spiethoff A, Kaumann V, et al. Primary clear cell carcinoma of noncirrhotic liver: immunohistochemical discrimination of hepatocellular and cholangiocellular origin. Dig Dis Sci. 1998; 43: 33–38.
[6] Liu Z, Ma W, Li H, et al. Clinicopathological and prognostic features of primary clear cell carcinoma of the liver. Hepatol Res. 2008; 38:291–299.
[7] Edmondson HA. Tumours of the liver and intrahepatic bile ducts. In: Atlas of tumor pathology. Washington DC: Armed Forces Institute of Pathology. 1958;49.
[8] Lai CL, Wu PC, Lam KC, et al. Histologic prognostic indicators in hepatocellular carcinoma. Cancer. 1979; 44:1677–1683.
[9] Li T, Fan J, Qin L X, et al. Risk factors, prognosis, and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol. 2011; 18(7): 1955-1963.
[10] Chen Z S, Zhu S L, Qi L N, et al. Long-term survival and prognosis for primary clear cell carcinoma of the liver after hepatectomy. Onco Targets Ther. 2016; 9: 4129-4135.
[11] McDermott WV, Cady B, Georgi B, et al. Primary cancer of the liver. Evaluation, treatment, and prognosis. Arch Surg. 1989; 124:552–554.
[12] Zhang Z, Xie H, Chen P, et al. Development and Identification of a Nomogram Prognostic Model for Patients with Primary Clear Cell Carcinoma of the Liver. Medical Science Monitor. 2020; 26.
[13] Liu Z, Ma W, Li H, et al. Clinicopathological and prognostic features of primary clear cell carcinoma of the liver. Hepatol Res. 2008; 38:291–299.
[14] Zhu SL, Zhong JH, Ke Y, et al. Efficacy of hepatic resection vs transarterial chemoembolization for solitary huge hepatocellular carcinoma. World J Gastroenterol. 2015; 21:9630–9637.
[15] Belghiti J, Noun R, Malafosse R, et al. Continuous versus intermittent portal triad clamping for liver resection: a controlled study. Ann Surg. 1999; 229:369.
[16] Yang SH, Watanabe J, Nakashima O, et al. Clinicopathologic study on clear cell hepatocellular carcinoma. Pathol Int. 1996; 46: 503–509.
[17] Xia Y, Yan ZL, Xi T, et al. A case-control study of correlation between preoperative serum AFP and recurrence of hepatocellular carcinoma after curative hepatectomy. Hepatogastroenterology. 2012; 59(119): 2248-2254.
[18] Luo Y, Ren F, Liu Y, et al. Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis. Int J Clin Exp Med. 2015;8(7):10235-10247.
[19] Park SK, Jung YK, Chung DH, et al. Factors influencing hepatocellular carcinoma prognosis after hepatectomy: a single-center experience. Korean J Intern Med. 2013;28(4):428-438.
[20] Wada H, Eguchi H, Nagano H, et al. Perioperative allogenic blood transfusion is a poor prognostic factor after hepatocellular carcinoma surgery: a multi-center analysis. Surg Today. 2018;48(1):73-79.
[21] Zhou L, Rui JA, Wang SB, et al. Outcomes and prognostic factors of cirrhotic patients with hepatocellular carcinoma after radical major hepatectomy. World J Surg. 2007;31(9):1782-1787.
[22] Shi C, Zhao Q, Liao B, et al. Anatomic resection and wide resection margin play an important role in hepatectomy for hepatocellular carcinoma with peritumoural micrometastasis. ANZ J Surg. 2019;89(11): E482-E486.
[23] Zhang X, Li J, Shen F, Lau WY. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2018;33(2):347-354.
[24] Liu QY, Li HG, Gao M, et al. Primary clear cell carcinoma in the liver: CT and MRI findings. World Journal Gastroenterol. 2011; 17(7): 946–952.
[25] Nagao T, Inoue S, Yoshimi F, et al. Postoperative recurrence of hepatocellular carcinoma. Ann Surg. 1990; 211:28–33.
[26] Fuster J, Garcia-Valdecasas JC, Grande L, et al. Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. Ann Surg. 1996; 223:297–302.
[27] Poon RT, Fan ST, Ng IO, et al. Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000; 3: 500–507.
[28] Dai X, Xue J, Hu J, et al. Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma. Transl Oncol. 2017;10(4):511-517.
[29] Dai T, Peng L, Lin G, et al. Preoperative elevated plasma fibrinogen level predicts tumor recurrence and poor prognosis in patients with hepatocellular carcinoma. J Gastrointest Oncol. 2019;10(6):1049-1063.
[30] Zhong FP, Zhang YJ, Liu Y, Zou SB. Prognostic impact of surgical margin in patients with hepatocellular carcinoma: A meta-analysis. Medicine (Baltimore). 2017;96(37): e8043.